Molecular breast imaging: a new technique using technetium Tc 99m scintimammography to detect small tumors of the

Deborah J Rhodes1, Michael K O'Connor, Stephen W Phillips

  • 1Department of Internal Medicine and Division of Preventive and Occupational Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA. rhodes.deborah@mayo.edu

Mayo Clinic Proceedings
|January 26, 2005
PubMed
Abstract

Insights

Molecular breast imaging (MBI) demonstrates high sensitivity in detecting small breast cancers, including those 1 cm or smaller. This advanced imaging technique shows promise, especially for women with dense breast tissue where mammography may be less effective.

Area of Science:

  • Radiology
  • Nuclear Medicine
  • Oncology

Background:

  • Mammography sensitivity can be limited by dense breast parenchyma.
  • Early detection of small breast cancers is crucial for improved patient outcomes.

Purpose of the Study:

  • To evaluate the sensitivity of molecular breast imaging (MBI) for detecting small breast cancers (<2 cm).

Main Methods:

  • A cadmium-zinc-telluride gamma camera was used to perform MBI on 40 women with suspicious lesions <2 cm.
  • Patients received technetium Tc 99m sestamibi, and imaging was performed immediately.
  • Standard craniocaudal and mediolateral oblique views were acquired with light compression.

Main Results:

  • MBI detected 33 of 36 malignant lesions (92% overall sensitivity).
  • For lesions ≤1 cm, MBI sensitivity was 86% (19 of 22 lesions).
  • MBI identified additional lesions missed by mammography in 4 patients, including contralateral findings.

Conclusions:

  • Molecular breast imaging reliably detects small malignant breast lesions (<2 cm).
  • MBI achieved a reported high sensitivity of 86% for lesions ≤1 cm.
  • MBI is particularly valuable for women with dense breasts, potentially improving cancer detection rates.